{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Study was early terminated during Phase 1 due to sponsor decision on 17 April 2019 (adverse events limited administration of higher doses required to achieve myeloablative conditioning necessary in this population). Hence, no participants were enrolled in Phase 2 and efficacy analysis were not performed in the both Phase 1 and 2."},"pointOfContact":{"email":"terry.nichols@mundipharma-rd.eu","organization":"Mundipharma Research Limited","phone":"(0044)1223424444","title":"Terry Nichols"}}